Table 2 Comparison of baseline characteristics of patients with acute and chronic central serous chorioretinopathy a,b
Acute CSC n = 26 | Chronic CSC n = 39 | |
|---|---|---|
Baseline logMAR ± SD | 0.07 ± 0.13 | 0.19 ± 0.25 |
Mean duration of symptoms (months) ± SD | 3.1 ± 1.9 | 73.7 ± 72.7 |
Minimum (months) | 0.2 | 7.3 |
Maximum (months) | 5.9 | 307.9 |
Previous treatment | ||
Eplerenon | 2 (7.7%) | 6 (15.4%) |
Acetazolamide | 2 (7.7%) | 6 (15.4%) |
NSAID eyedrops | 1 (3.9%) | 4 (10.3%) |
Argon laser | 2 (7.7%) | 5 (12.8%) |
Photodynamic therapy (PDT) | 0 (0.0%) | 8 (20.5%) |
Anti-VEGF | 2 (7.7%) | 14 (36%) |